A survey on applying machine learning techniques for management of diseases

EMF El Houby - Journal of Applied Biomedicine, 2018 - Elsevier
During the past years, the increase in scientific knowledge and the massive data production
have caused an exponential growth in databases and repositories. Biomedical domain …

Genetics of IL28B and HCV—response to infection and treatment

CN Hayes, M Imamura, H Aikata… - Nature reviews …, 2012 - nature.com
The IL28B locus attracted the attention of HCV researchers after a series of genome-wide
association studies independently identified a strong association between common IL28B …

Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options

Y Suzuki, K Ikeda, F Suzuki, J Toyota, Y Karino… - Journal of …, 2013 - Elsevier
Background & Aims Improved therapeutic options for chronic hepatitis C virus (HCV)
infection are needed for patients who are poor candidates for treatment with current …

FibroGENE: A gene-based model for staging liver fibrosis

M Eslam, AM Hashem, M Romero-Gomez, T Berg… - Journal of …, 2016 - Elsevier
Background & Aims The extent of liver fibrosis predicts long-term outcomes, and hence
impacts management and therapy. We developed a non-invasive algorithm to stage fibrosis …

Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C

MA Jiménez-Sousa, A Fernández-Rodríguez… - BMC medicine, 2013 - Springer
Background Since 2009, several studies have identified single-nucleotide polymorphisms
(SNPs) near the gene encoding for interleukin (IL)-28 (IL28B) that are strongly associated …

UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients

P Ramachandran, A Fraser, K Agarwal… - Alimentary …, 2012 - Wiley Online Library
Background The nonstructural 3 serine protease inhibitors (PI s), boceprevir and telaprevir,
represent the first in a new generation of directly acting antivirals against genotype 1 …

Serum WFA+‐M2BP is a non‐invasive liver fibrosis marker that can predict the efficacy of direct‐acting anti‐viral‐based triple therapy for chronic hepatitis C

K Ura, N Furusyo, E Ogawa, T Hayashi… - Alimentary …, 2016 - Wiley Online Library
Summary Background The Wisteria floribunda agglutinin‐positive human Mac‐2‐binding
protein (WFA+‐M2 BP) is a new liver fibrosis glycobiomarker with unique fibrosis‐related …

Host genetic variants in the pathogenesis of hepatitis C

M Rau, K Baur, A Geier - Viruses, 2012 - mdpi.com
Direct-acting antiviral drugs (DAAs) are currently replacing antiviral therapy for Hepatitis C
infection. Treatment related side effects are even worse and the emergence of resistant …

A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection

KC Chang, PL Tseng, YY Wu, HC Hung… - Clinical …, 2015 - Elsevier
Background & Aims Polymorphisms in interferon (IFN) L3 (encodes IFNλ3 or interleukin
28B) are associated with outcomes of treatment for hepatitis C virus (HCV) infection …

Relation of IL28B Gene Polymorphism with Biochemical and Histological Features in Hepatitis C Virus-Induced Liver Disease

JA Agundez, E Garcia-Martin, ML Maestro, F Cuenca… - PLoS …, 2012 - journals.plos.org
Background/Aims Polymorphism at the IL28B gene may modify the course of hepatitis C
virus (HCV) chronic infection. Our aim was to study the influence of IL28B rs12979860 gene …